Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Seelos Therapeutics, Inc.

Company calendar

Delayed OTC Markets 00:25:32 02/06/2026 HKT			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	+9,900.00%

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
22/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 90.45K 84.14K 76.53K 144K 9.8M 145K 1.01M 397K 5M 380K 372K 16.04M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 10.12M 9.42M 8.56M 16.17M 1.1B 16.24M 113M 44.4M 559M 42.56M 41.63M 1.79B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	100%	Yield 2022 *	-	Yield 2023	-

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
22/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
14/10/25	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
15/08/25	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
01/05/25	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
30/04/25	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
16/11/24	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
18/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
16/10/24	Top Midday Decliners	MT
15/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
28/09/24	Top Midday Decliners	MT
25/09/24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
25/09/24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

21/09/23	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
21/09/23	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
21/09/23	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
16/05/23	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
24/03/23	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Stock

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Valuation: Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news: Seelos Therapeutics, Inc.

Analysts' recommendations: Seelos Therapeutics, Inc.

Press Releases: Seelos Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Annual profits - Rate of surprise

22/11/24	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
25/10/24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
25/10/24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
15/10/24	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
15/10/24	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Current year	0		0.01
1 year	0		0.01
3 years	0		848.64
5 years	0		9,561.61
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	01/01/2019
Michael Golembiewski DFI	Director of Finance/CFO	54	01/09/2021
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
29/2/24	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
12/1/24	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%
12/1/24	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	+9,900.00%	-.--%	+9,900.00%	-100.00%	136
WUXI APPTEC CO., LTD.	-2.59%	-5.70%	+50.69%	+79.01%	70.61B
ARGENX SE	+0.60%	-9.82%	+5.02%	+52.50%	51.01B
LONZA GROUP AG	+0.42%	+0.10%	+8.69%	+33.32%	48.1B
IQVIA HOLDINGS INC.	+0.17%	-2.09%	+27.85%	+31.84%	42.78B
REVOLUTION MEDICINES, INC.	-0.25%	-8.59%	+289.44%	+684.50%	40.67B
BEONE MEDICINES AG	-0.96%	-3.15%	+7.10%	+98.75%	40.3B
CELLTRION, INC.	-2.13%	-1.64%	+8.63%	+46.15%	30.59B
WUXI BIOLOGICS (CAYMAN) INC.	-2.23%	-4.96%	+46.01%	+6.04%	28.16B
BIONTECH SE	-0.60%	-0.06%	-4.61%	-10.39%	24.36B
Average	+989.24%	-2.39%	+1,033.88%	+92.17%	37.66B
Weighted average by Cap.	-0.84%	-2.94%	+50.32%	+117.83%

	2022	2023
Net sales	-	2.2 1.97 1.83 1.66 3.14 213.21 3.16 22.03 8.63 108.7 8.27 8.09 348.83
Net income	-73.53M -65.67M -61.09M -55.57M -105M -7.12B -105M -735M -288M -3.63B -276M -270M -11.64B	-37.88M -33.83M -31.47M -28.63M -54.05M -3.67B -54.28M -379M -148M -1.87B -142M -139M -6B
Net Debt	4.59M 4.1M 3.81M 3.47M 6.55M 444M 6.58M 45.89M 17.98M 226M 17.23M 16.86M 727M	11.23M 10.03M 9.33M 8.49M 16.03M 1.09B 16.1M 112M 44.01M 554M 42.18M 41.26M 1.78B